EGFR and head and neck squamous cell carcinoma: Although several molecular targeting regimens such as cetuximab (an EGFR inhibitor) and bevacizumab (a vascular endothelial growth factor receptor inhibitor) have been developed, their clinical trials have had limited efficacy and unexpected toxicities have been reported; these outcomes have emphasized the difficulties in controlling HNSCC (2,3).